Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT
ContributorsNovak, Urban; Mooyaart, Jarl E; Daskalakis, Michael
Published inBone marrow transplantation, vol. 59, no. 11, p. 1631-1634
Publication date2024-11
First online date2024-08-27
Affiliation entities
Research groups
Citation (ISO format)
NOVAK, Urban et al. Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT. In: Bone marrow transplantation, 2024, vol. 59, n° 11, p. 1631–1634. doi: 10.1038/s41409-024-02401-4
Main files (1)
Article (Published version)
Identifiers
- PID : unige:182198
- DOI : 10.1038/s41409-024-02401-4
- PMID : 39192081
Additional URL for this publicationhttps://www.nature.com/articles/s41409-024-02401-4
Journal ISSN0268-3369
